amneal.com (AMRX) - Market Value to Book Value Ratio

Amneal Pharmaceuticals, Inc. (AMRX) - corporate logo

The development of Amneal Pharmaceuticals (AMRX) relies on the commercialization pace of complex biosimilars, where pricing pressure and debt require attention despite stable cash flows. Geopolitical tensions and raw material supply disruptions from Asia pose threats to mass production. This market valuation on GURU.Markets, where the metric stands at 211.37, confirms the company's status as a manufacturer of affordable medicines with a predictable free cash flow.

Amneal Corp (AMRX) - Market Value to Book Value from 07/04/2022 to 10/30/2026
Manufactured product of Amneal Pharmaceuticals Inc

This indicator compares the market value of shares with the company's net assets to determine the degree of business overvaluation relative to its actual capital. An analysis of the current price-to-book ratio allows for an assessment of the stability of Amneal Pharmaceuticals (AMRX), whose closed generics ecosystem and B2B partner loyalty create a reliable foundation even amidst regulatory pressure on margins.

Competitor analysis

HLN (Haleon plc) - Market Cap to Net Assets Ratio|Capitalization to Book Value Ratio KVUE|Market Value to Book Value Ratio Verona Pharma|Jyong Biotech Limited - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio LGND|PRGO (Perrigo Corp) - Market Value to Book Value|Market Capitalization to Book Value Ratio ALVO (Alvotech)|Market Capitalization to Book Value Ratio liquidia.com LQDA|GLPG - Market Value to Book Value Ratio|Market Value to Book Value ANIP (ANI Pharmaceuticals Inc)|MannKind Corp. (MNKD) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Amphastar Corp|PCRX (Pacira BioSciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ars-pharma.com|Market Cap to Net Assets Ratio TBPH (Theravance Biopharma, Inc.)|AQST (Aquestive Therapeutics Inc) - Market Value to Book Value|Market Value to Book Value Ratio scPharmaceuticals SCPH|Tectonic Therapeutic Inc. (TECX) - Market-to-Book Ratio|TNXP: Market Cap to Net Assets Ratio|China SXT Pharmaceuticals - Market Cap to Book Value Multiple|EPRX: Market Capitalization to Book Value Ratio|BioHarvest Sciences, Inc. - Market Value to Book Value|EXOZ (Invizyne Technologies, Inc.) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Oramed Pharma ORMP|Market Value to Book Value Ratio Entera Bio Ltd. (ENTX)|HYFT (ipatherapeutics.com) - Market Value to Book Value|Market Capitalization to Book Value Ratio ABVC (ABVC BioPharma, Inc.)|Market Capitalization to Book Value Ratio Cumberland Pharmaceuticals Inc CPIX|QNTM - Market Value to Book Value Ratio|FibroGen Corporation (FGEN) - Market Cap to Net Assets Ratio|Telomir Pharmaceuticals (TELO) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio RANI|SNYR (Synergy CHC Corp.) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Rallybio Corp. RLYB|Market Capitalization to Book Value Ratio LEXX|Market Capitalization to Book Value Ratio Pulmatrix Corporation (PULM)|Market Value to Book Value Ratio Pheton Holdings PTHL|Aptorum Group Ltd - Market Value to Book Value Ratio|LYRA: Market Cap to Net Assets Ratio|Market Value to Book Value IBO (impactbiomedinc.com)|tnfpharma.com (TNFA) - Market Value to Book Value Ratio|Market Capitalization to Net Assets YCBD (cbdMD)|PRFX (PainReform Ltd.) - Market Capitalization to Book Value Ratio|CYTO: Market Value to Book Value|Market Capitalization to Book Value Ratio LIPO|Market Capitalization to Book Value Ratio OptiNose Inc (OPTN)|Market Value to Book Value Ratio Pieris PIRS|Market Value to Book Value PROC|PTPI - Market Value to Book Value Ratio|qlsyy.net (QLI) - Market Cap to Net Assets Ratio|SLRN: Market Capitalization to Book Value Ratio|TFF Pharmaceuticals Inc. (TFFP) - Market Capitalization to Book Value Ratio